May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden Statement on Supreme Court Ruling to Restrict Emergency Room Care for Women
- Wyden Statement on HHS Watchdog Report on Lack of Oversight at Youth Residential Treatment Facilities
- Wyden Calls for Action to Stop PBM Middlemen from Flagrantly Flouting Medicare Rules that Protect Pharmacies
- Wyden Statement on Final Rules Promoting Good-Paying Clean Energy Jobs in America
- Wyden Statement at Finance Committee Hearing on Work and Social Security